Skip to content

BioNTech Stock Price Rallied 5.64% on Upbeat Q3 Earnings Results, $3.7 Billion Profit

BioNTech SE – ADR (NASDAQ: BNTX) stock rose 5.64% after reporting its Q3 2021 earnings on November 9, 2021.

The company reported a net profit of €3.2 billion ($3.7 billion) for the three months from July to September 2021 compared to a €210 million ($243 million) loss in Q3 2020.

The German pharmaceutical company generated almost €6.1 billion ($7.1 billion) in revenues during the period compared to €67.5 million ($78 million) in a similar period last year.

The pharmaceutical company’s windfall earnings are derived from its partnership with US pharma giant Pfizer in developing a COVID-19 vaccine that has been distributed globally since December 2020.

BioNTech’s total profit for the first nine months of the year adds up to €7.1 billion (8.2 billion) compared to a €351.7 million ($407 million) loss in a similar period last year.

In reaction to the Q3 earnings report, BioNTech shares rallied 5.64% during premarket trading.

*This is not investment advice.

BioNTech stock price.

Tradingview chart of BioNTech stock price 09-11-2021
Source: Tradingview

The BioNTech stock price rose 5.64% premarket to trade at $259.28, rising from Monday’s slicing price of $242.60.

Should you invest in BioNTech stock?

If you’re a smart investor, you will know that having large-cap stocks in your portfolio is vital. They are more mature companies, considered safer investments, trade with less volatility, have greater analyst coverage, and in most cases, have a steady dividend stream. Due to the current market environment, we think now is the perfect time to add large-cap stocks to your portfolio. But which large-cap shares should you buy? Our stock analysts regularly review the market and share their picks for some of the best large-caps to invest in.

Simon Mugo
Simon Mugo
Contributor

Simon has over six years of professional trading experience across FX, commodities and equities. He has a strong passion for financial markets and is particularly focused on price action trading

Stay ahead of the markets

Sign up to our free Morning Markets email, every weekday before the open.